The 17th European Biosimilars Congress 2024 covers topics such as:
- Chemical and Analytical Strategies for Biosimilars
- Current Challenges in Developing Biosimilars
- Biological Medicine
- Intellectual Property Rights
- Innovative Clinical Approach in Biosimilars
- Emerging Biosimilars in Therapeutics
- Biosimilars Development in Markets
- Regulatory Updates on Biosimilars
- Biopharmaceutical Informatics
- Biosimilars Approval to Biogenerics in Clinical Practice
- BCS and IVIVC Based Biowaivers
- Consequences of Brexit on Biosimilars
- Challenges in Biosimilars Pharmacovigilance
- Biosimilars Market and Cost Analysis
- Formulation Strategies for Follow-on Biologics
- Legal Issues and BPCI Act
- Biosimilars Research Pipeline
- Current Agency Expectations for Approval for Biosimilars
- Drug Delivery and Development
- Globalization of Biosimilars
- USFDA Approved Biosimilars
- Monoclonal Antibody Biosimilars
17th European Biosimilars Congress 2024 brings together Heads of Department, Directors, Scientists and Managers of: Product Patrimony, Laboratory Bioanalytics, Biopharmarceutical Technology, Global Marketing & Access, Regulatory Affairs, Strategy, Biopharmaceuticals, Operations, Biotechnical, Business Development and Documentation.
The 17th European Biosimilars Congress 2024 will be held in Madrid, Spain on 04-05 Apr 2024.
